Free Trial

Cogent Biosciences (COGT) Competitors

Cogent Biosciences logo
$12.07 -0.12 (-0.98%)
Closing price 07/25/2025 04:00 PM Eastern
Extended Trading
$12.06 -0.01 (-0.08%)
As of 07/25/2025 06:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

COGT vs. CRSP, PCVX, CYTK, MTSR, ADMA, KRYS, AKRO, RNA, PTCT, and ACLX

Should you be buying Cogent Biosciences stock or one of its competitors? The main competitors of Cogent Biosciences include CRISPR Therapeutics (CRSP), Vaxcyte (PCVX), Cytokinetics (CYTK), Metsera (MTSR), ADMA Biologics (ADMA), Krystal Biotech (KRYS), Akero Therapeutics (AKRO), Avidity Biosciences (RNA), PTC Therapeutics (PTCT), and Arcellx (ACLX). These companies are all part of the "pharmaceutical products" industry.

Cogent Biosciences vs. Its Competitors

Cogent Biosciences (NASDAQ:COGT) and CRISPR Therapeutics (NASDAQ:CRSP) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, valuation, dividends, profitability, institutional ownership, media sentiment, earnings and analyst recommendations.

In the previous week, CRISPR Therapeutics had 15 more articles in the media than Cogent Biosciences. MarketBeat recorded 18 mentions for CRISPR Therapeutics and 3 mentions for Cogent Biosciences. Cogent Biosciences' average media sentiment score of 0.90 beat CRISPR Therapeutics' score of 0.10 indicating that Cogent Biosciences is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Cogent Biosciences
2 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
CRISPR Therapeutics
5 Very Positive mention(s)
2 Positive mention(s)
4 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral

Cogent Biosciences has a net margin of 0.00% compared to CRISPR Therapeutics' net margin of -1,023.64%. CRISPR Therapeutics' return on equity of -20.08% beat Cogent Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Cogent BiosciencesN/A -149.79% -75.61%
CRISPR Therapeutics -1,023.64%-20.08%-17.13%

69.2% of CRISPR Therapeutics shares are owned by institutional investors. 7.3% of Cogent Biosciences shares are owned by company insiders. Comparatively, 4.3% of CRISPR Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Cogent Biosciences has a beta of 1.88, meaning that its share price is 88% more volatile than the S&P 500. Comparatively, CRISPR Therapeutics has a beta of 1.82, meaning that its share price is 82% more volatile than the S&P 500.

Cogent Biosciences currently has a consensus target price of $18.70, indicating a potential upside of 54.93%. CRISPR Therapeutics has a consensus target price of $71.31, indicating a potential upside of 10.12%. Given Cogent Biosciences' stronger consensus rating and higher possible upside, research analysts plainly believe Cogent Biosciences is more favorable than CRISPR Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cogent Biosciences
0 Sell rating(s)
3 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
2.82
CRISPR Therapeutics
1 Sell rating(s)
6 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.53

Cogent Biosciences has higher earnings, but lower revenue than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Cogent Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cogent BiosciencesN/AN/A-$255.86M-$1.84-6.56
CRISPR Therapeutics$37.31M149.90-$366.25M-$4.52-14.33

Summary

Cogent Biosciences beats CRISPR Therapeutics on 10 of the 16 factors compared between the two stocks.

Get Cogent Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for COGT and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding COGT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

COGT vs. The Competition

MetricCogent BiosciencesMED IndustryMedical SectorNASDAQ Exchange
Market Cap$1.39B$3.05B$5.70B$9.50B
Dividend YieldN/A2.37%4.58%4.01%
P/E Ratio-6.5621.1828.3920.08
Price / SalesN/A281.42431.1989.30
Price / CashN/A42.7636.2258.56
Price / Book9.148.378.675.88
Net Income-$255.86M-$55.19M$3.25B$258.89M
7 Day Performance-3.36%5.86%4.25%3.71%
1 Month Performance64.67%17.29%10.51%11.72%
1 Year Performance26.79%4.39%35.71%18.00%

Cogent Biosciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
COGT
Cogent Biosciences
3.6242 of 5 stars
$12.07
-1.0%
$18.70
+54.9%
+30.9%$1.39BN/A-6.5680
CRSP
CRISPR Therapeutics
2.4864 of 5 stars
$56.42
-0.7%
$71.75
+27.2%
+12.5%$4.87B$37.31M-12.48460Analyst Forecast
PCVX
Vaxcyte
1.7979 of 5 stars
$36.38
+1.3%
$136.50
+275.2%
-56.2%$4.69BN/A-9.12160News Coverage
Positive News
CYTK
Cytokinetics
4.1471 of 5 stars
$38.58
+4.2%
$70.92
+83.8%
-36.4%$4.61B$18.47M-7.29250News Coverage
MTSR
Metsera
N/A$42.47
+8.1%
$55.00
+29.5%
N/A$4.46BN/A0.0081Lockup Expiration
Gap Down
ADMA
ADMA Biologics
3.6078 of 5 stars
$18.68
+0.9%
$27.67
+48.1%
+37.7%$4.46B$426.45M21.98530News Coverage
KRYS
Krystal Biotech
4.8906 of 5 stars
$150.41
+1.5%
$213.75
+42.1%
-29.9%$4.35B$290.52M36.16210News Coverage
Analyst Forecast
AKRO
Akero Therapeutics
3.81 of 5 stars
$52.73
+2.2%
$82.50
+56.5%
+78.5%$4.20BN/A-27.0430Positive News
RNA
Avidity Biosciences
2.1407 of 5 stars
$33.57
+6.7%
$66.35
+97.7%
-18.9%$4.05B$8.93M-11.19190News Coverage
High Trading Volume
PTCT
PTC Therapeutics
4.4429 of 5 stars
$49.46
+1.9%
$65.00
+31.4%
+33.3%$3.92B$806.78M7.601,410News Coverage
Analyst Revision
ACLX
Arcellx
2.286 of 5 stars
$69.92
+1.4%
$111.23
+59.1%
+13.8%$3.85B$76.81M-23.3880News Coverage
Positive News

Related Companies and Tools


This page (NASDAQ:COGT) was last updated on 7/26/2025 by MarketBeat.com Staff
From Our Partners